Article

Efficacy of Fluticasone Propionate on Lung Function and Symptoms in Wheezy Infants

Division of Respiratory Medicine, Department of Pediatrics, Erasmus University MC/Sophia Children's Hospital, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands.
American Journal of Respiratory and Critical Care Medicine (Impact Factor: 11.99). 03/2005; 171(4):328-33. DOI: 10.1164/rccm.200402-227OC
Source: PubMed

ABSTRACT The role of inhaled corticosteroids in the treatment of recurrent or persistent wheeze in infancy remains unclear. We evaluated the effect of 3 months of treatment with inhaled fluticasone propionate, 200 microg daily (FP200), on lung function and symptom scores in wheezy infants. Moreover, we evaluated whether infants with atopy and/or eczema respond better to FP200 as compared with non-atopic infants. Forced expiratory flow (Vmax(FRC)) was measured at baseline and after treatment. Sixty-five infants were randomized to receive FP200 or placebo, and 62 infants (mean age, 11.3 months) completed the study. Mean Vmax(FRC), expressed as a Z score, was significantly below normal at baseline and after treatment in both groups. The change from baseline of Vmax(FRC) was not different between the two treatment arms. After 6 weeks of treatment, and not after 13 weeks, the FP200 group had a significantly higher percentage of symptom-free days and a significant reduction in mean daily cough score compared with placebo. Separate analysis of treatment effect in infants with atopy or eczema showed no effect modification. We conclude that in wheezy infants, after 3 months of treatment with fluticasone, there was no improvement in lung function and no reduction in respiratory symptoms compared with placebo.

Download full-text

Full-text

Available from: Anna A P H Vaessen-Verberne, Aug 30, 2015
0 Followers
 · 
93 Views
  • Source
    • "Those with a positive family history, over 2 years and frequent symptoms show the best response to inhaled steroids. However one study using inhaled Fluticazone to wheezy infants showed no improvement in lung function.44 It is suggested that after a trial of 3 months of inhaled corticosteroids, treatment should be withdrawn in those who become almost completely free of wheeze to assess the need for ongoing therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The diagnosis and management of asthma in young children is difficult, since there are many different wheezy phenotypes with varying underlying aetiologies and outcomes. This review discusses the different approaches to managing young children with wheezy illnesses presented in recently published global guidelines. Four major guidelines published since 2007 are considered. Helpful approaches are presented to assist the clinician to decide whether a clinical diagnosis of asthma can, or should be made in a young child with a recurrent wheezy illness and which treatments would be appropriate, dependent on risk factors, age of presentation, response to initial treatment and safety considerations. Each of the guidelines provide useful information for clinicians assessing young children with recurrent wheezy illnesses. There are differences in classification of the disease and treatment protocols. Although a firm diagnosis of asthma may only be made retrospectively in some cases and there are several effective guidelines to initiating treatment. Consistent review of the need for ongoing treatment with a particular pharmacological modality is essential, since many children with recurrent wheezing in infancy go into spontaneous remission. It is probable that newer biomarkers of airway inflammation will assist the clinician as to when to initiate and when to continue pharmacological treatment in the future.
    Allergy, asthma & immunology research 01/2010; 2(1):1-13. DOI:10.4168/aair.2010.2.1.1 · 3.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objetivos: evaluar la utilidad de incorporar estrategias de participación de los alumnos a un curso de formación continuada. Métodos: seleccionamos ocho escenarios clínicos pediátricos, que implicaban la toma de decisiones diagnósticas y/o terapéuticas, para las que la evidencia disponible no permitía establecer recomendaciones precisas. Los alumnos recibían con anterioridad documentación de cada escenario con un caso clínico, una serie de preguntas, una guía de búsqueda e interpretación y publicaciones recientes relacionadas. En el curso se recogieron las contestaciones a las preguntas antes y después de las ponencias realizadas por un grupo de expertos. Analizamos la idoneidad y concordancia de las respuestas con respecto a las recomendaciones realizadas por los expertos. Resultados: de los 126 alumnos, obtuvimos información de 105 cuestionarios iniciales y 83 finales. La concordancia de las respuestas entre alumnos y expertos aumentó globalmente de la encuesta inicial a la final. Considerando las preguntas de cada escenario con una única respuesta recomendada, este aumento fue del 56,2% (IC95%: 53,9 a 58,5) al 76,3% (IC 95%: 74 a 78,5). Los artículos enviados, junto con los escenarios clínicos, influyeron en general poco o nada en las respuestas (mediana, 69,7%; rango, 50 a 78,8%), salvo para el escenario 3, en el que una guía de práctica clínica española influyó en la mitad de las contestaciones. Sin embargo, la opinión de los expertos influyó mucho o bastante en las respuestas (mediana, 69,9%; rango 48,1 a 87,5%). Conclusiones: las contestaciones ofrecidas por los pediatras representados en el curso muestran una gran variabilidad, siendo algunas de ellas inadecuadas. El escaso impacto de la literatura científica publicada sobre la toma de decisiones contrasta con la gran influencia de la opinión de expertos. La incorporación de estrategias de participación activa en la formación continuada tiene un efecto cuantificable sobre nuestro nivel de conocimientos y nuestra capacidad para tomar decisiones. Palabras clave: educación médica continua; pautas en la práctica de los médicos; toma de decisiones; aprendizaje basado en problemas.
    01/2009; 33(1).
Show more